Our pipeline of Optejet® products is focused on improving the usability and administration of eye drop medications.
Our current focus is the Phase 3 development of MicroPine, our atropine formulation administered using the Optejet for the reduction of pediatric myopia, plus ease of use and adherence.
Setting a target on unmet needs
MicroPine (Myopia)
MicroPine is our atropine formulation and candidate for the treatment of pediatric myopia progression. With the Optejet children can self-administer medication while minimizing dose-related side effects. The Optejet’s digital monitoring Optecare™ services will help physicians and parents ensure their children are getting the medication they need.
U.S. Addressable Market $1.8B
EYEN-510, EYEN-520, EYEN-530, and others (Dry Eye)
Dry Eye Disease is a common ocular condition and is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms, such as discomfort and visual disturbance1.
EYEN-510 is a combination product collaboration between SGN Nanopharma’s micellar nanoparticle cyclosporine formulation, SGN-101, and the Optejet® for the treatment of chronic dry eye disease.
EYEN-520 is a combination product collaboration between Senju’s SJP-0035 formulation, fonadlepar, a peroxisome proliferator-activated receptor delta agonist for the adjunctive treatment of chronic dry eye disease, administered using the Optejet®.
EYEN-530 is a combination product collaboration between Formosa Pharmaceuticals’ formulation of clobetasol propionate ophthalmic suspension 0.05% and the Optejet for the short-term relief of dry eye disease. Clobetasol propionate is a potent steroid that was approved by the U.S. FDA on March 4, 2024, for the reduction of post-surgical inflammation and pain.
Eyenovia is evaluating other potential dry eye candidates for development in combination with the Optejet. Using the Optejet, dry eye sufferers will conveniently be able to dose themselves with their dry eye medication.
U.S. Addressable Market $5.5B
1. Jennifer P. Craig, et al., TFOS DEWS II Definition and Classification Report, The Ocular Surface, Volume 15, Issue 3, 2017, Pages 276-283